Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M5049 PK/PD in Healthy Japanese and Caucasian Participants
NCT04880213Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (6 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time, Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity and 5 more. Started May 2021; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04880213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880213.